S. Ortiz-Urda

发表

DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics.

Alfonso Latorre, Á. Somoza, A. Celli, 2014, Nanoscale.

Modeling inducible human tissue neoplasia identifies an extracellular matrix interaction network involved in cancer progression.

Howard Y. Chang, Howard Y Chang, Jason A. Reuter, 2009, Cancer cell.

NRAS mutant melanoma – undrugable?

C. Posch, S. Ortiz-Urda, 2013, Oncotarget.

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo

M. Dimon, A. Daud, P. Leboit, 2013, Proceedings of the National Academy of Sciences.

Pathogenesis of the permeability barrier abnormality in epidermolytic hyperkeratosis.

P. Elias, K. Feingold, D. Crumrine, 2001, The Journal of investigative dermatology.

Type VII Collagen Is Required for Ras-Driven Human Epidermal Tumorigenesis

D. Veitch, P. Khavari, Lei Chen, 2005, Science.

Merkel cell carcinoma: mitoses, expression of Ki‐67 and bcl‐2 correlate with disease progression

F. Breier, A. Steiner, C. Posch, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

Oncogenic KIT mutations in different exons lead to specific changes in melanocyte phospho-proteome.

A. Burlingame, J. Rodríguez-Peralto, J. Ma, 2016, Journal of proteomics.

Detection of GNAQ mutations and reduction of cell viability in uveal melanoma cells with functionalized gold nanoparticles

D. Char, Alfonso Latorre, Á. Somoza, 2015, Biomedical microdevices.

A localized variant of paraneoplastic pemphigus: acantholysis associated with malignant melanoma

D. Metze, J. Bauer, W. Salmhofer, 2001, The British journal of dermatology.

LncRNAs as Biomarkers for Melanoma LncRNAs as Biomarkers for Melanoma

S. Ortiz-Urda, Yixuan Zheng, R. Moreno, 2018 .

Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients

C. Posch, M. Sanlorenzo, I. Vujic, 2014, British Journal of Cancer.

Melanoma risk during immunomodulating treatment

A. Daud, A. Algazi, M. Sanlorenzo, 2022, Melanoma research.

A laminin-collagen complex drives human epidermal carcinogenesis through phosphoinositol-3-kinase activation.

D. Veitch, P. Khavari, Clara N. Dey, 2007, Cancer research.

The Plant Lectin Wheat Germ Agglutinin Inhibits the Binding of Pemphigus Foliaceus Autoantibodies to Desmoglein 1 in a Majority of Patients and Prevents Pathomechanisms of Pemphigus Foliaceus In Vitro and In Vivo

K. Wolff, J. Smolle, A. Elbe-Bürger, 2003, The Journal of Immunology.

Mycoplasma pneumoniae‐associated mucositis – case report and systematic review of literature

C. Posch, M. Sanlorenzo, I. Vujic, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue.

P. Khavari, D. Keene, M. Marinkovich, 2003, The Journal of clinical investigation.

Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer

M. Kay, P. Khavari, D. Keene, 2003, Gene Therapy.

Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.

A. Daud, Sara Alcántara Luna, P. Quaglino, 2015, JAMA dermatology.

The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma

A. Burlingame, M. Dimon, A. Daud, 2018, Scientific Reports.

Mutant NRASQ61 shares signaling similarities across various cancer types – potential implications for future therapies

D. Arneson, Adam J. Yen, C. Posch, 2014, Oncotarget.

Searching for the Chokehold of NRAS Mutant Melanoma.

C. Posch, M. Sanlorenzo, I. Vujic, 2016, The Journal of investigative dermatology.

Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer

Adam J. Yen, R. Esteve-Puig, C. Posch, 2014, Oncotarget.

Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma

N. Ahmad, C. Posch, M. Sanlorenzo, 2015, The Journal of investigative dermatology.

MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and ‘wild type’ melanomas

C. Posch, M. Sanlorenzo, Jeffrey Ma, 2018, Oncotarget.

Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells

R. Esteve-Puig, C. Posch, M. Sanlorenzo, 2016, Oncotarget.

Cutting edge in medical management of cutaneous oncology.

S. Arron, A. Daud, K. Chong, 2012, Seminars in cutaneous medicine and surgery.

The risk of melanoma in airline pilots and cabin crew: a meta-analysis.

John Kornak, Wolfgang Kainz, Christian Posch, 2015, JAMA dermatology.

Chapter 2 LncRNAs as Biomarkers for Melanoma

S. Ortiz-Urda, Yixuan Zheng, R. Traspas, 2018 .

New insights in melanoma biomarkers: long-noncoding RNAs.

M. Sanlorenzo, I. Vujic, S. Ortiz-Urda, 2016, Melanoma management.

The long non-coding RNA ‘TRASH’ is essential for cell survival in MAPK-driven melanoma

A. Daud, Y. Kohwi, T. Kohwi-Shigematsu, 2022 .

Stable nonviral genetic correction of inherited human skin disease

P. Khavari, D. Keene, B. Thyagarajan, 2002, Nature Medicine.

The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial

S. Behr, A. Daud, B. Bastian, 2015, British Journal of Cancer.

Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma.

A. Daud, P. Quaglino, A. Algazi, 2014, Journal of the American Academy of Dermatology.

Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma

J. Kahn, P. Curl, I. Vujic, 2014, PloS one.

φC31 Integrase-Mediated Nonviral Genetic Correction of Junctional Epidermolysis Bullosa

P. Khavari, D. Keene, B. Thyagarajan, 2003 .

Brief Report fC31 Integrase-Mediated Nonviral Genetic Correction of Junctional Epidermolysis Bullosa

P. Khavari, D. Keene, B. Thyagarajan, 2003 .

A phase I trial of BKM120 combined with vemurafenib in BRAFV600E/k mutant advanced melanoma.

P. Munster, A. Daud, A. Algazi, 2014 .

Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS‐mutant and wild‐type melanoma

P. Chapman, A. Daud, A. Algazi, 2018, Pigment cell & melanoma research.

Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo

R. Panzer‐Grümayer, G. Green, C. Posch, 2016, Oncotarget.

The risk of melanoma in pilots and cabin crew: UV measurements in flying airplanes.

J. Cleaver, P. Quaglino, C. Posch, 2015, JAMA dermatology.

A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E/K mutant advanced melanoma

P. Munster, A. Daud, A. Algazi, 2019, Pigment cell & melanoma research.

The burden of malignant melanoma--lessons to be learned from Austria.

D. Kivaranovic, W. Oberaigner, M. Hackl, 2016, European journal of cancer.

Single-point mutation detection in RNA extracts using gold nanoparticles modified with hydrophobic molecular beacon-like structures.

Christian Posch, Álvaro Somoza, Alfonso Latorre, 2014, Chemical communications.

Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells.

A. Burlingame, R. Panzer‐Grümayer, G. Green, 2016, The Journal of investigative dermatology.

Melanoma risk perception and prevention behavior among African-Americans: the minority melanoma paradox

M. Sanlorenzo, I. Vujic, S. Ortiz-Urda, 2015, Clinical, cosmetic and investigational dermatology.

Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment

K. Rappersberger, S. Ortiz-Urda, V. Feichtenschlager, 2023, Oncotarget.

Pemphigus Foliaceus In Vitro and In Vivo Patients and Prevents Pathomechanisms of Autoantibodies to Desmoglein 1 in a Majority of the Binding of Pemphigus Foliaceus The Plant Lectin Wheat Germ Agglutinin Inhibits

K. Wolff, J. Smolle, A. Elbe-Bürger, 2012 .

This information is current as Pemphigus Foliaceus In Vitro and In Vivo of Patients and Prevents Pathomechanisms of Autoantibodies to Desmoglein 1 in a Majority Inhibits the Binding of Pemphigus Foliaceus The Plant Lectin Wheat Germ Agglutinin

K. Wolff, J. Smolle, A. Elbe-Bürger, 2003 .

Stable nonviral genetic correction of inherited human skin disease

P. Khavari, D. Keene, B. Thyagarajan, 2002 .

Carbamazepine‐induced DRESS syndrome with recurrent fever and exanthema

R. Kunstfeld, E. Heere‐Ress, S. Ortiz-Urda, 2004, International journal of dermatology.

Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells

R. Esteve-Puig, C. Posch, M. Sanlorenzo, 2016, Oncotarget.

Human Multipotent Stem Cell Proteins Induce Apoptosis in Skin Cancer Cells

G. Naughton, C. Posch, S. Ortiz-Urda, 2013 .

Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells.

R. Esteve-Puig, C. Posch, M. Sanlorenzo, 2016, Oncotarget.

Melanoma risk perception and prevention behavior among African-Americans: the minority melanoma paradox

M. Sanlorenzo, I. Vujic, S. Ortiz-Urda, 2015 .

The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma

A. Burlingame, M. Dimon, A. Daud, 2018, Scientific Reports.

Correction: Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma

J. Kahn, P. Curl, I. Vujic, 2015, PLoS ONE.

Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells

R. Esteve-Puig, C. Posch, I. Vujic, 2016, OncoTarget.

Cutting edge in medical management of cutaneous oncology.

S. Arron, A. Daud, S. Ortiz-Urda, 2012, Seminars in cutaneous medicine and surgery.

Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression.

A. Daud, Sara Alcántara Luna, P. Quaglino, 2015, JAMA dermatology.

DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics.

Alfonso Latorre, A. Celli, C. Posch, 2014, Nanoscale.

Cutaneous CD56+ T-cell lymphoma developing during pembrolizumab treatment for metastatic melanoma

L. Pincus, S. Ortiz-Urda, Yixuan Zheng, 2018, JAAD case reports.

The therapeutically actionable long non-coding RNA ‘T-RECS’ is essential to cancer cells’ survival in NRAS/MAPK-driven melanoma

Y. Kohwi, T. Kohwi-Shigematsu, C. Posch, 2024, Molecular cancer.

Human Multipotent Stem Cell Proteins Induce Apoptosis in Skin Cancer Cells

G. Naughton, C. Posch, S. Ortiz-Urda, 2013 .

Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma

J. Kahn, P. Curl, I. Vujic, 2014, PloS one.

PhiC31 integrase-mediated nonviral genetic correction of junctional epidermolysis bullosa.

P. Khavari, D. Keene, B. Thyagarajan, 2003, Human Gene Therapy.